Digital illustration showing a cheerful scientist beside a beaker, a bullish stock chart, and a small cartoon bull — symbolizing Revvity’s blend of biotech innovation, strong institutional backing, and renewed investor optimism.

Some Funds Are Adding and Analysts Are Rather Bullish: Should You Buy Shares of Revvity (RVTY)?

Revvity (RVTY) may not make flashy headlines, but it’s quietly building a powerful comeback story. With top institutions buying, analysts turning bullish, and profits stabilizing, this former PerkinElmer spinout is morphing into a biotech value gem. Here’s why investors — and scientists — are both smiling (in lab coats).

Read entire article